478510-98-4

Basic information

• Product Name: 5-METHYL-[2'-13C]URIDINE
• Synonyms: [2'-13C]RIBOTHYMIDINE;5-METHYL-[2'-13C]URIDINE;5-Methyluridine-2'-13C
• CAS NO: 478510-98-4
• Molecular Formula: C10H14N2O6
• Molecular Weight: 259.24
• Product Categories: Carbohydrates & Derivatives, Heterocycles, Isotope Labeled Compounds, Nucleotides, Bases & Related Reagents
• Mol File: 478510-98-4.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-METHYL-[2'-13C]URIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-METHYL-[2'-13C]URIDINE(478510-98-4)
• EPA Substance Registry System: 5-METHYL-[2'-13C]URIDINE(478510-98-4)

Safety Data

• Hazardous Substances Data: 478510-98-4(Hazardous Substances Data)

Usage

Description

5-METHYL-[2'-13C]URIDINE, also known as Labeled 5-Methyluridine, is a primary degradation product of tRNA. It is a urinary nucleoside that has been identified as a biological marker for patients with colorectal cancer. The presence of 13C labeling in the 2' position of the uridine molecule allows for its detection and analysis in various research and diagnostic applications.

Uses

Used in Colorectal Cancer Research:
5-METHYL-[2'-13C]URIDINE is used as a biological marker for the detection and monitoring of colorectal cancer. The presence of this labeled nucleoside in urine samples can indicate the presence of colorectal cancer, aiding in early diagnosis and treatment planning.
Used in Diagnostic Applications:
5-METHYL-[2'-13C]URIDINE is used as a diagnostic tool for identifying patients with colorectal cancer. The analysis of this labeled nucleoside in urine samples can provide valuable information about the disease progression and help in the development of personalized treatment strategies.
Used in Pharmaceutical Research:
5-METHYL-[2'-13C]URIDINE is used as a research tool in the development of new drugs and therapies for colorectal cancer. The unique properties of this labeled nucleoside can help researchers understand the underlying mechanisms of the disease and identify potential targets for therapeutic intervention.
Used in Clinical Trials:
5-METHYL-[2'-13C]URIDINE is used as a biomarker in clinical trials for colorectal cancer. The measurement of this labeled nucleoside in urine samples can help assess the efficacy of new treatments and monitor the response of patients to various therapeutic interventions.

Upstream product

• 159496-08-9 C₄⁽¹³⁾C₅H₁₆O₇S 
• 7288-28-0 2,4-bis(trimethylsiloxy)-5-methylpyrimidine 
• 503173-73-7 [glu-13C6]-1,2:5,6-di-O-isopropylidene-3-oxo-α-D-glucofuranose 
• 159496-09-0 [13C5]-1,2-di-O-acetyl-3,5-di-O-benzoyl-α,β-D-ribofuranose 
• 65-71-4 thymin 
• 126590-65-6 <1,2,3,4,5,6-13C6>-1,2:5,6-di-O-isopropylidene-α-D-glucofuranose 
• 503173-75-9 ¹³C₅-1′, 2 ′-di-O-acetyl-3 ′ ,5 ′-di-O-benzoyl-β-D-ribofuranose 
• 503173-74-8 [ribose-13C5]-3,5-di-O-benzoyl-1,2-O-isopropylidene-α-D-ribofuranose 
• 238096-51-0 <1,2,3,4,5-13C5>-1,2-O-isopropylidene-α-D-ribofuranose 
• 503173-76-0 [ribose-13C5]-1-(2-O-acetyl-3,5-di-O-benzoyl-β-D-ribofuranosyl)-5-methyluracil 

Relevant articles and documents

NMR Spectroscopic Determination of the Solution Structure of a Branched Nucleic Acid from Residual Dipolar Couplings by Using Isotopically Labeled Nucleotides

Only a small set of magnetic-field-induced residual dipolar couplings is required to determine the global structure of branched nucleic acids. This is demonstrated for the example of the Holliday junction (shown schematically) after 13C labelin

A multigram, stereoselective synthesis of D-[13C5]ribose from D-[13C6]glucose and its conversion into [13C5]nucleosides

The preparation of 13C-labeled ribonucleosides starting from D-[13D6]glucose in 45% overall yield is described. The key of this short synthetic way is the dehomologation of di-O-isopropylidene hexofuranose 2 with periodic acid and NaBH4 that afforded stereoselectively the labeled ribofuranose derivative 3 in high yield.